CT, thanks. Wouldn't you think that CytoDyn knows by now how many deaths occurred in each arm, which is the primary endpoint? And secondarily, didn't the FDA want to see the unblinded data asap? If we hit the primary endpoint, shouldn't that be sufficient for leronlimab to be granted EUA?